660440-47-1

Upstream product

• 102152-63-6 3-(p-carbetoxyphenyl)butyric acid 
• 660440-46-0 3-(R)-(4-hydroxymethylphenyl)-N-((S)-2-hydroxy-1-phenylethyl)-butyramide 
• 67-56-1 methanol 
• 660440-45-9 4-[(R)-2-((S)-2-hydroxy-1-phenylethylcarbamoyl)-1-methylethyl]benzoic acid ethyl ester 
• 926009-93-0 3-(4-hydroxymethyl-phenyl)-butyric acid 

Downstream Products

• 926010-03-9 3-(4-{3-[3-methoxy-4-(3-o-tolyl-ureido)-phenyl]-2-oxo-2H-pyridin-1-ylmethyl}-phenyl)-butyric acid methyl ester 
• 926009-94-1 (R)-3-(4-methanesulfonyloxymethylphenyl)butyric acid methyl ester 

Relevant academic research and scientific papers

Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists

A series of pyridone-N-benzyl-propanoic acids have been optimised to afford potent orally bioavailable VLA-4 antagonists.

ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES

The present invention relates to novel compounds of formula (I), processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.

NOVEL COMPOUNDS

The present invention relates to novel pyridone derivatives capable of inhibiting a4 integrin medicated cell adhesion, processes for their preparation, compositions comprising them and their use in the treatment of diseases capable of being modulated by t